Patents by Inventor Gary Schoolnik
Gary Schoolnik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11572588Abstract: The present invention provides novel markers of treatment response in a subject infected with Mycobacterium, which allow for quantifying treatment impact on the physiologic state of the Mycobacterium.Type: GrantFiled: July 19, 2018Date of Patent: February 7, 2023Assignees: The Regents of the University of Colorado, a body corporate, The Regents of the University of California, Yale University, Colorado State University Research Foundation, The Board of Trustees of the Leland Standford Junior UniversityInventors: Nicholas D. Walter, Martin Voskuil, Gary Schoolnik, Gregory Dolganov, J. Lucian Davis, Payam Nahid, Greg Robertson, Anne Lenaerts
-
Publication number: 20220042076Abstract: A method includes coupling a molecular diagnostic test device to a power source. A biological sample is conveyed into a sample preparation module. The device is then actuated by only a single action to cause the device to perform the following functions without further user action. First, the device heats the sample via a heater of the sample preparation module to lyse a portion of the sample. Second, the device conveys the lysed sample to an amplification module and heats the sample within a reaction volume of the amplification module to amplify a nucleic acid thereby producing an output solution containing a target amplicon. The device then reacts, within a detection module, each of (i) the output solution and (ii) a reagent formulated to produce a signal that indicates a presence of the target amplicon within the output solution. A result associated with the signal is then read.Type: ApplicationFiled: October 22, 2021Publication date: February 10, 2022Applicant: Visby Medical, Inc.Inventors: Boris ANDREYEV, Victor BRIONES, Ryan T. CENA, Adam DE LA ZERDA, Colin KELLY, Gregory LONEY, Gary SCHOOLNIK, David SWENSON
-
Patent number: 11168354Abstract: A method includes coupling a molecular diagnostic test device to a power source. A biological sample is conveyed into a sample preparation module. The device is then actuated by only a single action to cause the device to perform the following functions without further user action. First, the device heats the sample via a heater of the sample preparation module to lyse a portion of the sample. Second, the device conveys the lysed sample to an amplification module and heats the sample within a reaction volume of the amplification module to amplify a nucleic acid thereby producing an output solution containing a target amplicon. The device then reacts, within a detection module, each of (i) the output solution and (ii) a reagent formulated to produce a signal that indicates a presence of the target amplicon within the output solution. A result associated with the signal is then read.Type: GrantFiled: November 9, 2020Date of Patent: November 9, 2021Assignee: Visby Medical, Inc.Inventors: Boris Andreyev, Victor Briones, Ryan T. Cena, Adam De La Zerda, Colin Kelly, Gregory Loney, Gary Schoolnik, David Swenson
-
Patent number: 11162130Abstract: A method includes coupling a molecular diagnostic test device to a power source. A biological sample is conveyed into a sample preparation module. The device is then actuated by only a single action to cause the device to perform the following functions without further user action. First, the device heats the sample via a heater of the sample preparation module to lyse a portion of the sample. Second, the device conveys the lysed sample to an amplification module and heats the sample within a reaction volume of the amplification module to amplify a nucleic acid thereby producing an output solution containing a target amplicon. The device then reacts, within a detection module, each of (i) the output solution and (ii) a reagent formulated to produce a signal that indicates a presence of the target amplicon within the output solution. A result associated with the signal is then read.Type: GrantFiled: November 9, 2018Date of Patent: November 2, 2021Assignee: Visby Medical, Inc.Inventors: Boris Andreyev, Victor Briones, Ryan T. Cena, Adam De La Zerda, Colin Kelly, Gregory Loney, Gary Schoolnik, David Swenson
-
Publication number: 20210299669Abstract: The disclosure relates generally to molecular diagnostic devices configured to amplifying a single nucleotide polymorphism (SNP) locus and discriminate between two or more allelic variants of the SNP, indicating presence or absence of a target allele. In some embodiments, the molecular diagnostic devices are capable of detecting, at point-of-care, SNPs associated with resistance or susceptibility to antibiotic treatment of bacterial infections. In other aspects, the disclosure provides methods of treatment for disease or disorders (e.g. bacterial infections) where treatment is guided by presence or absence of an allele at a SNP locus as determined by such molecular diagnostic devices.Type: ApplicationFiled: September 3, 2019Publication date: September 30, 2021Inventors: David SWENSON, Phoebe CAO, Gary SCHOOLNIK, Bryan D. KNYSH, Teresa M. ABRAHAM
-
Publication number: 20210071236Abstract: A method includes coupling a molecular diagnostic test device to a power source. A biological sample is conveyed into a sample preparation module. The device is then actuated by only a single action to cause the device to perform the following functions without further user action. First, the device heats the sample via a heater of the sample preparation module to lyse a portion of the sample. Second, the device conveys the lysed sample to an amplification module and heats the sample within a reaction volume of the amplification module to amplify a nucleic acid thereby producing an output solution containing a target amplicon. The device then reacts, within a detection module, each of (i) the output solution and (ii) a reagent formulated to produce a signal that indicates a presence of the target amplicon within the output solution. A result associated with the signal is then read.Type: ApplicationFiled: November 9, 2020Publication date: March 11, 2021Applicant: Visby Medical, Inc.Inventors: Boris ANDREYEV, Victor BRIONES, Ryan T. CENA, Adam DE LA ZERDA, Colin KELLY, Gregory LONEY, Gary SCHOOLNIK, David SWENSON
-
Publication number: 20200248259Abstract: The present invention provides novel markers of treatment response in a subject infected with Mycobacterium, which allow for quantifying treatment impact on the physiologic state of the Mycobacterium.Type: ApplicationFiled: July 19, 2018Publication date: August 6, 2020Inventors: Nicholas D. Walter, Martin Voskuil, Gary Schoolnik, Gregory Dolganov, Lucian J. Davis, Payam Nahid, Greg Roberston, Anne Lenaerts
-
Publication number: 20190169677Abstract: A method includes coupling a molecular diagnostic test device to a power source. A biological sample is conveyed into a sample preparation module. The device is then actuated by only a single action to cause the device to perform the following functions without further user action. First, the device heats the sample via a heater of the sample preparation module to lyse a portion of the sample. Second, the device conveys the lysed sample to an amplification module and heats the sample within a reaction volume of the amplification module to amplify a nucleic acid thereby producing an output solution containing a target amplicon. The device then reacts, within a detection module, each of (i) the output solution and (ii) a reagent formulated to produce a signal that indicates a presence of the target amplicon within the output solution. A result associated with the signal is then read.Type: ApplicationFiled: November 9, 2018Publication date: June 6, 2019Applicant: Click Diagnostics, Inc.Inventors: Boris ANDREYEV, Victor BRIONES, Ryan T. CENA, Adam DE LA ZERDA, Colin KELLY, Gregory LONEY, Gary SCHOOLNIK, David SWENSON
-
Publication number: 20110206715Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb. isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be reintroduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: ApplicationFiled: April 2, 2010Publication date: August 25, 2011Inventors: MARCEL BEHR, PETER SMALL, GARY SCHOOLNIK, MICHAEL A. WILSON
-
Patent number: 7700118Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tubercuosis to attenuate the pathogenic bacteria.Type: GrantFiled: March 14, 2008Date of Patent: April 20, 2010Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Publication number: 20080254052Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tubercuosis to attenuate the pathogenic bacteria.Type: ApplicationFiled: March 14, 2008Publication date: October 16, 2008Inventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Patent number: 7364740Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: GrantFiled: June 1, 2005Date of Patent: April 29, 2008Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Publication number: 20060002953Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: ApplicationFiled: June 1, 2005Publication date: January 5, 2006Inventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael Wilson
-
Publication number: 20040265337Abstract: This invention provides immunogenic compositions containing attenuated bacteria (such as Salmonella enterica) which are resistant to the antimicrobial actions of human defensins, particularly human defensin 5 (HD-5). Methods for using these compositions to elicit a sustained and highly specific immune response are provided. The invention also provides methods for preparing vaccines wherein a heterologous antigen is expressed by the defensin-resistant bacteria.Type: ApplicationFiled: August 21, 2003Publication date: December 30, 2004Inventors: Krisztina M. Zsebo, Roymarie Ballester, Gary Schoolnik, Steven M. Julio, Andrew F. Giusti
-
Publication number: 20040063923Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: ApplicationFiled: August 21, 2003Publication date: April 1, 2004Inventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Patent number: 6686166Abstract: Specific genetic deletions are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: GrantFiled: June 27, 2001Date of Patent: February 3, 2004Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Publication number: 20040018574Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tbThe genetic markers can be used for diagnosis of M. tb. infection. One or more antigens provided from the genetic markers can be used in diagnostic assays, e.g. a serological assay.Type: ApplicationFiled: March 14, 2003Publication date: January 29, 2004Inventors: Marcel Behr, Peter Small, Michael A. Wilson, Gary Schoolnik, Claus Aagaard, Ida Rosenkrands, Karin Weldingh, Peter Andersen
-
Publication number: 20020176873Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: ApplicationFiled: June 27, 2001Publication date: November 28, 2002Inventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Patent number: 6291190Abstract: Specific genetic deletions are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: GrantFiled: May 25, 1999Date of Patent: September 18, 2001Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson